LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Bought by Barclays PLC

Barclays PLC grew its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 394.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 36,577 shares of the medical instruments supplier’s stock after purchasing an additional 29,180 shares during the period. Barclays PLC owned approximately 0.16% of LeMaitre Vascular worth $3,396,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. MML Investors Services LLC increased its holdings in LeMaitre Vascular by 2.8% in the 3rd quarter. MML Investors Services LLC now owns 7,107 shares of the medical instruments supplier’s stock worth $660,000 after buying an additional 191 shares during the period. XTX Topco Ltd purchased a new stake in shares of LeMaitre Vascular in the 3rd quarter valued at $344,000. DF Dent & Co. Inc. raised its holdings in shares of LeMaitre Vascular by 26.2% during the third quarter. DF Dent & Co. Inc. now owns 258,767 shares of the medical instruments supplier’s stock worth $24,037,000 after purchasing an additional 53,797 shares during the last quarter. State Street Corp lifted its position in LeMaitre Vascular by 3.6% during the third quarter. State Street Corp now owns 822,085 shares of the medical instruments supplier’s stock valued at $76,363,000 after purchasing an additional 28,525 shares during the period. Finally, Stifel Financial Corp boosted its holdings in LeMaitre Vascular by 10.8% in the third quarter. Stifel Financial Corp now owns 72,194 shares of the medical instruments supplier’s stock valued at $6,706,000 after purchasing an additional 7,060 shares during the last quarter. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at LeMaitre Vascular

In related news, Director Bridget A. Ross sold 3,750 shares of LeMaitre Vascular stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $101.47, for a total transaction of $380,512.50. Following the transaction, the director now owns 2,278 shares in the company, valued at approximately $231,148.66. This trade represents a 62.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 10.79% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Oppenheimer restated an “outperform” rating and issued a $93.00 target price (up previously from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Cantor Fitzgerald assumed coverage on shares of LeMaitre Vascular in a research note on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price objective on the stock. Barrington Research lifted their price objective on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a report on Friday, November 1st. Finally, StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, LeMaitre Vascular has a consensus rating of “Moderate Buy” and an average price target of $94.57.

LeMaitre Vascular Trading Down 0.8 %

LMAT stock opened at $91.38 on Tuesday. The business’s 50-day moving average is $97.74 and its 200 day moving average is $90.16. LeMaitre Vascular, Inc. has a 12-month low of $52.88 and a 12-month high of $109.58. The stock has a market cap of $2.05 billion, a price-to-earnings ratio of 49.93, a PEG ratio of 2.47 and a beta of 0.93.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, beating the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The firm had revenue of $54.82 million during the quarter, compared to the consensus estimate of $53.50 million. During the same period in the prior year, the company earned $0.33 EPS. The firm’s revenue was up 15.6% compared to the same quarter last year. As a group, equities analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st were issued a $0.16 dividend. The ex-dividend date of this dividend was Thursday, November 21st. This represents a $0.64 dividend on an annualized basis and a yield of 0.70%. LeMaitre Vascular’s payout ratio is 34.97%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.